A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35350598/
We assessed physicians' experiences of prescribing once-weekly (OW) semaglutide to patients with type 2 diabetes (T2D) in Canada. Physicians who had prescribed OW semaglutide to ≥2 patients with T2D in...
Conclusion: The survey suggests that physicians are satisfied with the OW semaglutide clinical effects.
Weight Loss Outcomes With Telemedicine During COVID-19
Source : https://www.frontiersin.org/articles/10.3389/fendo.2022.793290/full
BackgroundAmidst the COVID-19 pandemic, telemedicine was rapidly implemented to maintain patient care during quarantine. However, there is little data on how this transition may have impacted weight loss outcomes and...
Conclusion: Patients on anti-obesity medications who were followed for 6 months via video or video plus in-person visits (hybrid) experienced clinically significant weight loss. Median number of AOMs were similar among groups, and the most common AOMs were metformin, semaglutide 1.0 mg, and topiramate. More investigation is required to compare...
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333446/
Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient...
Conclusions: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity
Injectable semaglutide and reductions in HbA1c and weight in the real-world in people switched from alternative glucagon-like peptide 1 receptor agonists - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35322528/
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work demonstrated differential reductions in HbA1c and weight dependent...
Conclusion: The analysis, in this research letter, demonstrates decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide – potentially...
How to reset metabolic setpoint in obesity management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35320198/
The metabolic setpoint theory is based upon the premise that there is a barohomeostatic mechanism in humans which maintains weight within a predetermined range. This is viewed as an obstacle...
Conclusion/Relevance: The metabolic setpoint theory is based upon the premise that there is a barohomeostatic mechanism in humans which maintains weight within a predetermined range. This is viewed as an obstacle to weight loss, but can also be considered an opportunity to reset the barometabolic